Weight-loss drugs like Ozempic may be up for Medicare price negotiations — will Trump support it?
Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...
Barchart on MSN59m
Analyst: Sell ‘Magnificent 7’ Stocks and Buy These 3 Dividend Stocks Instead
Analysts have mixed opinions on BMY, with a “Moderate Buy” consensus from 25 analysts. Seven rate it a “Strong Buy,” 17 recommend “Hold,” and one suggests “Sell.” The average price target is $59.52, ...
Medicare Drug Price Explanations Shed Some Light on Future Talks
The Biden administration’s justification of the first cycle of Medicare drug price negotiations is fueling curiosity and ...
BioSpace9h
The Megaround Ruled Biopharma in 2024 as First-Time VC Funding Doubled
Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 ...
Bristol Myers price target raised to $65 from $62 at Truist
Truist raised the firm’s price target on Bristol Myers (BMY) to $65 from $62 and keeps a Buy rating on the shares as part of a broader research ...
FiercePharma7d
Bristol Myers celebrates 10 years of Opdivo with FDA approval for subcutaneous version
Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...
Bristol Myers to report Q4 IPRD/licensing expense of $18M
Bristol Myers Squibb (NYSE:BMY) said it expects to report a Q4 net expense of $18M related to acquired IPRD and licensing ...